Immunocompromised patients
Immunocompromised patients are the most likely to gain from enhanced bactericidal activity possibly offered by lactamaminoglycoside combination therapy 9 In a comparison of lactam monotherapy with lactamaminoglycoside combination therapy restricted to patients with neutropenia we found no advantage to combination treatment 89 Although the approach to the management of patients with and without neutropenia is separated in clinical practice this similarity supports a biological basis underlying our results .
They will carry you through the atmosphere wherever and whenever you choose.